Latest Breaking News On - Trust ii trial - Page 1 : comparemela.com

D. Ross Camidge, MD, PhD, discusses the rationale for the ongoing phase 2 TRUST-II trial of taletrectinib in patients with non–small cell lung cancer harboring ROS1 mutations. 

United statesD ross camidgeThoracic oncology clinical programUniversity of colorado health lung cancer clinicThoracic oncology clinical research programRoss camidgeColorado health lung cancer clinicAnschutz medical campusLung cancerTrust ii trialPatients with non small cell lung cancer harboring ros1 mutationsUniversity of colorado health lung cancer clinic anschutz medical campus